Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharmacol Exp Ther ; 303(2): 563-73, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12388637

ABSTRACT

In vascular smooth muscle, increased expression of cyclooxygenase-2 (COX-2) has emerged as an important mechanism for regulation of prostanoid synthesis influenced by vessel injury, cytokines, and growth factors. We have investigated how COX-2 participates in angiotensin II (ANG II)-mediated cell responses in cultured human vascular smooth muscle cells (VSMCs). ANG II type 1 (AT1) receptors induce increased accumulation of COX-2, both at the mRNA and protein levels. ANG II increased transcription of the COX-2 gene; also, nuclear extracts from stimulated cells had increased NF-kappa B binding to its DNA consensus sequence. ANG II-induced COX-2 expression was markedly blunted by inhibition of mitogen-activated protein kinase. Furthermore, the ANG II-induced increase in COX-2 protein abundance was attenuated by both the peroxisome proliferator-activated receptor alpha (PPARalpha) activator Wy-14,643 [pyrinixic acid; 4-chloro-6-(2,3-xylidino)-2-pyrimidinyl) thioacetic acid] and the PPARgamma activator 15d-PGJ2 (15-deoxy-Delta(12-14)-prostaglandin J2). Not only did ANG II increase COX-2 expression and prostaglandin synthesis, ANG II-stimulated DNA synthesis and cell migration were dependent on COX-2 activity. PPARalpha and PPARgamma activators inhibited ANG II-stimulated DNA synthesis and cell migration. These results suggest that ANG II enhances COX-2 expression at the transcription level; also, COX-2 activity plays an important role in mediating ANG II- induced proliferation and migration of VSMCs, suggesting the possibility of magnification of ANG II effects over time due to the induction of COX-2 expression. These results also demonstrate that both the alpha and gamma type of PPAR activators inhibit COX-2 expression induced by angiotensin II in VSMCs which may have therapeutic significance in vascular diseases.


Subject(s)
Angiotensin II/pharmacology , Isoenzymes/biosynthesis , Muscle, Smooth, Vascular/enzymology , Prostaglandin-Endoperoxide Synthases/biosynthesis , Angiotensin II/antagonists & inhibitors , Blotting, Northern , Cell Division/drug effects , Cell Movement/drug effects , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cells, Cultured , Cyclooxygenase 2 , DNA/biosynthesis , Electrophoresis , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation, Enzymologic/drug effects , Humans , Immunoblotting , Membrane Proteins , Mitosis/drug effects , Muscle, Smooth, Vascular/chemistry , Muscle, Smooth, Vascular/drug effects , Precipitin Tests , Prostaglandins/metabolism , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, Cytoplasmic and Nuclear/agonists , Reverse Transcriptase Polymerase Chain Reaction , Stimulation, Chemical , Transcription Factors/agonists
SELECTION OF CITATIONS
SEARCH DETAIL
...